A Semiquantitative Risk Assessment Methodology Fit for Biopharmaceutical Life Cycle Stages

References

1. 1.↵
   International Conference for Harmonisation, Quality Guideline Q9: Quality Risk Management. ICH: Geneva, 2005.
2. 2.↵
   International Conference for Harmonisation, Quality Guideline Q10: Pharmaceutical Quality System. ICH: Geneva, 2008.
3. 3.↵
   U.S. Food and Drug Administration, Guidance for Industry: Process Validation: General Principles and Practices. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2011.
4. 4.↵
   U.S. Food and Drug Administration, Pharmaceutical cGMP's for the 21st century-A Risk-Based Approach. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2004.
5. 5.↵
   Parenteral Drug Association Inc. Technical Report No. 54: Implementation of Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations; Bethesda, MD, 2012.
6. 6.↵
   1. Strong J. C.,
   2. McDermott T. S.,
   3. Heinzerling O.,
   4. Claycamp H. G.

   The Risk of Trusting Risk Priority Numbers, AAPS Newsmagazine, Feb 2017. https://www.aapsnewsmagazine.org/aapsnewsmagazine/articles/2017/feb17/cover-story-feb17 (accessed January 1, 2019)
7. 7.↵
   1. Zaborenko N.,
   2. Shi Z.,
   3. Corredor C. C.,
   4. Smith-Goettler B. M.,
   5. Zhang L.,
   6. Hermans A.,
   7. Neu C. M.,
   8. Alam M. A.,
   9. Cohen M. J.,
   10. Lu X.,
   11. Xiong L.,
   12. Zacour B. M.

   First-Principles and Empirical Approaches to Predicting in Vitro Dissolution for Pharmaceutical Formulation and Process Development and for Product Release Testing. AAPS J. 2019, 21 (3), 32.

   OpenUrl
8. 8.↵
   U.S. Food and Drug Administration, Guidance for Industry: SUPAC: Manufacturing Equipment Addendum. Center for Biologics Evaluation and Research. U.S. Department of Health and Human Services: Rockville, MD, 2011.
9. 9.↵
   1. Shebl N. A.,
   2. Franklin cB. D.,
   3. Barber N.

   Failure Mode and Effects Analysis Outputs: Are They Valid? BMC Health Serv. Res. 2012, 12 (1), 150.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Peacos P.

    Bias: The Hidden Danger to Your Risk Assessment. Am. Pharm. Rev. 2016, 19 (2), 184365.

    OpenUrl
11. 11.↵
    1. Crickette G.,
    2. Demian R.,
    3. Fox C.,
    4. Hatch J.,
    5. Makomaski J.,
    6. Mazumdat R.,
    7. McGuir R.

    Exploring Risk Appetite and Risk Tolerance—RIMS Executive Report: The Risk Perspective. Risk and Insurance Management Society, 2012.
12. 12.↵
    1. Razzaghi F.

    Quality Risk Management. FDA Advisory Committee of the Office of Pharmaceutical Science Manufacturing Subcommittee, July 20, 2004.
13. 13.↵
    International Conference for Harmonisation, Quality Guideline Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management. ICH: Geneva, 2017.
14. 14.↵
    International Conference for Harmonisation, Quality Guideline Q8(R2): Pharmaceutical Development. ICH: Geneva, 2009.
15. 15.↵
    International Conference for Harmonisation, Quality Guideline Q11: Development and Manufacture of Drug Substances. ICH: Geneva, 2012.